000			03327nam a22003615i 4500
999			_c76613 _d76613 _x1
001			76613
003			ES-MaUEC
005			20230202102144.0
007			cr nn 008mamaa
008			100301s2006 sz | s |||| 0|eng d
020			_a9783764374389
024	7		_a10.1007/3-7643-7438-1 _2doi
040			_dES-MaUEC
050		4	_aQR185.8.T84 _bW456 2006
100	1		_aWeinberg, Jeffrey M. _eeditor literario _985764 _0Local
245	1	0	_aTNF-alpha Inhibitors _cedited by Jeffrey M. Weinberg, Robin Buchholz.
260			_aBasel _bSpringer International Publishing _c2006
300			_a1 recurso en línea (IX, 133 p.) _b10 ilustraciones
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aMilestones in Drug Therapy
505	0		_ato TNF/pathophysiology of TNF -- History of development of TNF inhibitors -- Pharmacology of TNF inhibitors -- Etanercept in rheumatology -- Etanercept in dermatology and off-label use -- Infliximab in rheumatology -- Infliximab in dermatology, gastroenterology, and off-label use -- Adalimumab in rheumatology -- Adalimumab in dermatology -- A review of the safety of the tumor necrosis inhibitors infliximab, etanercept, and adalimumab.
520			_aOver the last decade, the advent of biologic agents has greatly revolutionized therapeutic medicine in the management of chronic inflammatory diseases, such as rheumatoid arthritis, Crohnâ€{u3824}isease, and psoriasis. Elucidation of the complex web of cytokine network and the roles of these cytokines in the pathogenesis of inflammatory disorders provided one of the key catalysts for the advancement of targeted biologic therapy in autoimmune and inflammatory diseases. TNF-alpha is known to play a crucial role in the pathogenesis of many chronic inflammatory diseases. Elevated levels of TNF-alpha have been demonstrated in Crohnâ€{u3824}isease, psoriasis, psoriatic arthritis, and rheumatoid arthritis, suggesting a role for TNF-alpha in their pathogenesis. Although TNF-alpha plays a critical role in the activation of innate and acquired immune responses, the persistence of the immune response and inappropriate production of TNF-alpha can produce pathological changes resulting from chronic inflammation and tissue damage. This volume provides a comprehensive overview of the development, pharmacology, efficacy, and safety of the currently available TNF-alpha inhibitors â€{u0974}anercept, infliximab, and adalimumab. The most recent preclinical and clinical data is presented on this topic, which should be of interest to the preclinical researcher, the clinician, and the patient who wants to learn more about these therapies.
650		7	_2embne _aInmunología _9138330
700	1		_aBuchholz, Robin _eeditor literario _985765 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/3-7643-7438-1 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12822310 _b10-10-17 _c01-10-14
942			_2lcc _cLE
945			_aQR185.8.T84 W456 2006 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11551525 _z06-04-17
988			_aEBSPRINGER
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _gsz _h0